Libido Dampeners — Drugs and Conditions That Suppress Sexual Desire

Status: draft compiled 2026-04-28.

The literature on libido dampeners is unusually scattered for something so often complained about. It lives partly in psychiatry (antidepressants, antipsychotics), partly in oncology (androgen-deprivation therapy), partly in dermatology (5α-reductase inhibitors, antiandrogens for acne and hair loss), partly in addiction medicine (opioids, alcohol, cannabis), partly in cardiology and endocrinology (beta blockers, statins, thyroid disease, prolactinomas), and partly in transgender medicine (cyproterone, spironolactone, bicalutamide, GnRH analogues). What unifies these threads is that "low libido" sits at the end of several mechanistically distinct pipelines: hypothalamic-pituitary-gonadal (HPG) axis suppression with low testosterone or estradiol, direct androgen-receptor blockade, raised prolactin, raised SHBG with low free androgens, serotonergic dampening of dopaminergic reward, blunted nitric-oxide signalling in genital vasculature, and CNS-level suppression of motivation through neurosteroid loss or chronic cortisol elevation. A drug or condition can engage one mechanism, several, or — as with cyproterone, methadone, or finasteride — a tangled combination that explains why effects are large but textbook descriptions stay vague. The goal here is to walk through the major classes with effect sizes where they are known, mechanism where it is real, and per-paragraph confidence rather than the diffuse "may cause sexual side effects" hedge that drug labels favour. Sources: orientation only. Confidence: C2.

The selective serotonin reuptake inhibitors (SSRIs) and serotonin-noradrenaline reuptake inhibitors (SNRIs) are the most-studied iatrogenic libido dampeners, and the prevalence numbers are not subtle. The Spanish multicentre prospective study of 1,022 outpatients by Montejo and colleagues remains the canonical reference: sexual dysfunction emerged in 57.7% on fluoxetine, 62.9% on sertraline, 62.3% on fluvoxamine, 70.7% on paroxetine, and rose further with venlafaxine and citalopram, with bupropion and mirtazapine far lower. A 2009 meta-analysis by Serretti and Chiesa pooled trials across the class and found treatment-emergent sexual dysfunction rates ranging from roughly 25% with bupropion at one end to over 70% with sertraline, paroxetine, fluoxetine, and venlafaxine at the other, with mirtazapine, moclobemide, agomelatine, amineptine, and nefazodone lower than the SSRIs as a class. The decomposition matters because patients and prescribers often hear "SSRIs can affect sex drive" without being told that paroxetine roughly doubles the rate seen with bupropion in the same trial framework. Sources: Montejo et al. 2001, PMID 11229449, Serretti & Chiesa 2009, PMID 19440080, Montejo-Gonzalez et al. 1997, PMID 9292833. Confidence: C1 for the rough hierarchy, C2 for individual numbers because of differing rating instruments.

Mechanistically, SSRI-induced libido suppression is not a single lesion but a pile of 5-HT-mediated effects on top of the dopaminergic and nitrergic systems that drive desire and arousal. Increased synaptic serotonin acts on 5-HT2A and 5-HT2C receptors to inhibit mesolimbic dopamine release, and on 5-HT3 receptors to dampen orgasmic reflex pathways, while reduced central nitric oxide signalling impairs the genital arousal response. Bupropion, by raising synaptic dopamine and noradrenaline without serotonergic loading, sits cleanly outside this pathway, which is why its baseline sexual-dysfunction rate is near placebo and why it is the most-used switch and adjunct strategy. Mirtazapine's relatively low rate (around 25% in head-to-head studies versus 60% for escitalopram) is usually attributed to its 5-HT2A and 5-HT2C antagonism, which directly blocks the serotonergic brake on dopamine. Vortioxetine has been shown in randomised, controlled trials in healthy adults not to impair sexual function relative to placebo, in contrast to paroxetine in the same comparison, and in pooled phase-3 data treatment-emergent sexual adverse events were 1.6-1.8% on vortioxetine versus 1.0% on placebo — although clinicians should treat the "placebo-like" framing cautiously because depression itself depresses libido. Vilazodone, despite its 5-HT1A partial-agonist profile, behaves more like a typical SSRI on most sexual endpoints. Sources: Clayton et al. 2019 (vortioxetine vs paroxetine RCT), PMID 31405765, Jacobsen et al. (vilazodone vs citalopram), PMC4457500, Boyarsky et al. 1999 (mirtazapine sexual function), PMID 10431683, La Torre et al. 2013 review. Confidence: C2.

Treatment of SSRI-induced sexual dysfunction is the practical consequence of all of this. The strongest evidence supports adjunctive bupropion 150-300 mg/day, which restored function in roughly two-thirds of patients in the seminal Ashton 1998 case series and in a 2001 randomised trial by Clayton, with a later double-blind RCT by Safarinejad in male SRI-treated patients showing significant benefit on multiple IIEF domains. Lower-dose 150 mg/day formulations have shown weaker results, suggesting a real dose-response. Switching to bupropion or mirtazapine outright is a related strategy with reasonable RCT support, as is switching to vortioxetine in patients with treatment-emergent SSRI sexual dysfunction (Jacobsen et al. and Montejo et al. each documented improvement). Adding sildenafil works for the erectile component but does little for desire; PT-141 (bremelanotide), an MC4-receptor agonist that increases dopamine release in the medial preoptic area, is FDA-approved for hypoactive sexual desire disorder in premenopausal women and is being used off-label for SSRI-related desire loss. Drug holidays (skipping doses on weekends) work for short-half-life agents like sertraline and paroxetine but not for fluoxetine, whose long-lived norfluoxetine metabolite makes pharmacokinetic dips impractical. Sources: Ashton et al. 1998, PMID 9541153, Clayton et al. 2004 (bupropion SR RCT), PMID 11894796, Safarinejad 2010 BJU Int, Kingsberg et al. 2019 (bremelanotide RECONNECT). Confidence: C2.

Post-SSRI sexual dysfunction (PSSD) is the harder problem, and it is the place where the antidepressant story stops looking like a routine pharmacology chapter and starts looking like a contested clinical entity. The phenomenon — genital anesthesia, reduced or absent libido, anorgasmia, pleasureless orgasm, and emotional blunting that persist for months to years after SSRI/SNRI discontinuation — was first described in case reports by Bahrick and others in the early 2000s. After a citizen petition led by Healy and the RxISK group, the European Medicines Agency's Pharmacovigilance Risk Assessment Committee concluded in May 2019 that sexual dysfunction can be long-lasting after SSRI/SNRI discontinuation in some patients, and required label changes across the class; Health Canada issued a similar safety communication in 2021. The mechanism remains genuinely unknown. Hypotheses include persistent epigenetic downregulation of 5-HT1A receptors via methyl-CpG-binding protein-mediated changes, durable serotonin-dopamine circuit alterations, neurosteroid disruption (the same family of changes implicated in post-finasteride syndrome — see below), and possibly a peripheral small-fibre neuropathy in genital tissue. Estimating prevalence is hard because spontaneous-reporting databases are biased, controlled cohorts have rarely been built, and depressive relapse confounds attribution; Healy and colleagues' 2023 estimate of around one in 216 patients prescribed serotonergic antidepressants developing PSSD is heavily caveated. The honest reading is: PSSD is real enough to have triggered regulator action, but the population incidence and pathobiology are still open questions. Sources: EMA PRAC 2019 SSRI/SNRI label update, Healy et al. 2023 risk estimation, Ann Gen Psychiatry, Bala et al. 2018 (PSSD literature review), Reisman 2017 PSSD review. Confidence: C2 for existence and EMA recognition, C4 for mechanism, C4 for incidence figures.

The antiandrogens used in transgender hormone therapy, prostate cancer, and paraphilic-disorder protocols are far more direct libido dampeners, and their mechanisms are correspondingly clearer. Spironolactone, the dominant transfeminine antiandrogen in North America, is fundamentally a competitive androgen-receptor antagonist that displaces testosterone and DHT from the AR, with secondary inhibition of 17α-hydroxylase and 17,20-lyase that becomes meaningful at higher doses. Its AR affinity is modest — substantially lower than cyproterone or bicalutamide — and it lowers testosterone less reliably than CPA at equivalent clinical doses. Its libido-suppressive effect in transfeminine people is therefore real but not maximal; cisgender women taking 100-200 mg/day for hirsutism or PCOS often report dampened libido but not the abolitive change seen with CPA. Cyproterone acetate (CPA) is mechanistically more potent: it is both a strong AR antagonist and a progestin that profoundly suppresses gonadotropin secretion, which is why its testosterone-lowering effect is large enough to mimic surgical castration in prostate-cancer literature, with corresponding "severe suppression of sex drive and erectile potency". The ENIGI study and subsequent dose-finding work showed that 5-10 mg/day CPA achieves near-maximal testosterone suppression in trans women, well below historical 50-100 mg doses, reducing the over-suppression and depressive flattening that high-dose protocols produced. Sources: Pharmacodynamics of spironolactone (review), Corvol et al. 1975, PMID 166833, Kuhl 2005 review of progestins, Meyer et al. 2020 ENIGI low-dose CPA, PMID 34125226. Confidence: C2.

Bicalutamide is structurally and pharmacologically distinct: a non-steroidal pure AR antagonist with no progestogenic, oestrogenic, or 5α-reductase activity. Because it does not enter the brain efficiently, blockade of pituitary AR is incomplete, the negative feedback on the HPG axis is disinhibited, and serum LH and testosterone actually rise rather than fall. In a male this means circulating testosterone climbs, often roughly doubling, and is partly aromatised to oestradiol — hence the high gynaecomastia rate when bicalutamide is used as monotherapy. The libido effect is genuine because peripheral AR is blocked, but it is achieved despite high serum testosterone, not via low testosterone. Combining bicalutamide with a GnRH agonist (combined androgen blockade) collapses both the receptor signal and the circulating ligand. Sources: Furr & Tucker 1996, PMID 8560673, Masiello et al. 2002, JBC, Pharmacology of bicalutamide review. Confidence: C2.

GnRH agonists like leuprolide, goserelin, and triptorelin produce "chemical castration" by paradoxical pituitary desensitisation: continuous (rather than pulsatile) GnRH-receptor stimulation initially provokes an LH and testosterone surge — the "flare" — but within 2-4 weeks the pituitary downregulates GnRH receptors and gonadotropin output collapses, dropping serum testosterone to castrate levels (<50 ng/dL, often <20). GnRH antagonists like degarelix and the oral relugolix achieve the same endpoint by direct competitive blockade without flare, with castrate testosterone reached in about 3 days versus 28 days for leuprolide. The libido-suppressive effect is essentially complete in most patients on either regimen and is the basis for their use in advanced prostate cancer, central precocious puberty, and selected paraphilia treatment programmes. Abiraterone goes further by inhibiting CYP17A1, the enzyme that runs both 17α-hydroxylase and 17,20-lyase reactions in adrenal, gonadal, and intra-tumoral steroidogenesis; it suppresses serum and urinary androgens by more than 90% from baseline, but because it also blocks cortisol synthesis, it requires concurrent prednisone. Sources: Van Poppel et al. 2020 IJU review, Klotz et al. 2008 (degarelix vs leuprolide), Attard et al. 2008 (abiraterone CYP17), PMID 18645193, de Bono et al. 2011 NEJM (abiraterone phase 3). Confidence: C1.

Finasteride and dutasteride are 5α-reductase inhibitors used at 1 mg and 0.5 mg respectively for androgenetic alopecia and at 5 mg for benign prostatic hyperplasia. Their stated mechanism is straightforward: they block conversion of testosterone to dihydrotestosterone, the more potent AR ligand at scalp and prostate. The randomised-trial sexual side-effect rate in the original PROPECIA trials was small — roughly 2-4% with finasteride versus 1-2% on placebo across libido, erection, and ejaculation endpoints — and most cases resolved with continuation or discontinuation. The complication is that 5α-reductase also produces neuroactive steroids: progesterone is converted via 5α-dihydroprogesterone to allopregnanolone, a potent positive allosteric modulator of GABA-A receptors, and analogous reductions occur in 3α,5α-tetrahydrodeoxycorticosterone (THDOC) and 5α-dihydrotestosterone-derived 3α-androstanediol. Allopregnanolone deficiency has been mechanistically linked to anxiety, depression, and altered reward signalling, which gives finasteride a plausible CNS footprint independent of the simple AR-pathway story. Sources: Kaufman et al. 1998 PROPECIA Phase III, PMID 9777765, Belelli & Lambert 2005 (allopregnanolone neurosteroid review), PMID 15959466, Traish 2018 epigenetics review. Confidence: C2.

Post-finasteride syndrome (PFS) is the analogue to PSSD: a contested entity in which patients report persistent sexual, neuropsychiatric, and somatic symptoms after stopping finasteride, including persistent low libido, erectile dysfunction, anorgasmia, penile and genital sensory loss, depression, anxiety, and cognitive complaints. Melcangi's group at the University of Milano-Bicocca has produced the most consistent biomarker work, documenting altered cerebrospinal fluid neurosteroid profiles (including reduced allopregnanolone) and abnormal pudendal somatosensory evoked potentials in PFS patients with severe ED, the latter being the first objective evidence of a peripheral neuropathy in this cohort. The FDA's August 2022 PROPECIA label revision added depression and suicidal ideation/behavior under nervous-system/psychiatric adverse reactions, after similar updates by the EMA and France's ANSM. The agency also stated that the available data did not establish causation for persistent sexual dysfunction beyond what is already labelled. The honest read is that PFS, like PSSD, has cleared the bar of "real enough to label-warn" but has not cleared the bar of "well-defined incidence and pathobiology"; the discrepancy between the low rate in original trials and the loud anecdotal cohort is unresolved, and pre-existing depression, body-image distress in alopecia patients, and a real but rare neuroendocrine phenotype probably all contribute in different patients. Sources: Melcangi et al. 2017 J Steroid Biochem Mol Biol, PMID 28408350, Giatti et al. 2018 review, PMID 29675596, PROPECIA 2022 FDA label, PFS Foundation/FDA petition history. Confidence: C2 for existence and label changes, C4 for mechanism and incidence.

Hyperprolactinemia-inducing drugs are the next major class, and the dopamine biology here is unusually clean. Tuberoinfundibular dopamine neurons tonically inhibit pituitary lactotrophs through D2 receptors. Antipsychotics that potently and persistently block D2 — risperidone, paliperidone, haloperidol, and the depot phenothiazines — disinhibit prolactin secretion, often raising it three- to ten-fold above the upper limit. Elevated prolactin in turn suppresses GnRH pulsatility and lowers LH, FSH, and gonadal sex-steroid production, while also acting on central reward circuitry and tyrosine hydroxylase expression to blunt sexual desire and erectile capacity through testosterone-independent mechanisms. The clinical picture is decreased libido (37.8% in risperidone studies), erectile dysfunction (32%), and ejaculatory disorders (33%). Atypical antipsychotics with looser D2 binding (quetiapine, olanzapine, ziprasidone) raise prolactin less; clozapine often does not raise it at all. Aripiprazole is the standout because it is a D2 partial agonist: at the lactotroph it provides just enough dopaminergic tone to keep prolactin in range, and adjunctive aripiprazole in placebo-controlled trials normalised prolactin in around half of risperidone-induced hyperprolactinemia cases and reduced sexual side effects in parallel. Outside antipsychotics, the prokinetics metoclopramide and (in some markets) domperidone block central D2 receptors and can raise prolactin, although domperidone's poor CNS penetration limits its impact compared with metoclopramide. Sources: Park et al. 2012 review, PMC3623530, Kelly et al. 2016 BJP adjunctive aripiprazole RCT, PMC4998932, Buvat & Lemaire 1997 hyperprolactinemia review, PMID. Confidence: C1 for the mechanism and direction, C2 for specific rates.

Opioid-induced androgen deficiency (OPIAD) is the cleanest example of HPG-axis suppression as a mechanism for low libido. Chronic mu-opioid-receptor agonism — whether from oxycodone, fentanyl, methadone, or sustained-release morphine — suppresses hypothalamic GnRH pulsatility through opioid receptors on kisspeptin and GnRH neurons, producing secondary (hypogonadotropic) hypogonadism with low LH, low FSH, and low testosterone, and analogous suppression of estradiol and ovulation in women. The prevalence depends on the diagnostic threshold used, but cohorts of chronic-pain and opioid-maintenance patients give figures of 19% to 86%, with rates rising at daily oral morphine equivalents above 100-200 mg. Methadone consistently produces more profound hypogonadism than buprenorphine in head-to-head studies, plausibly because buprenorphine is a partial mu agonist with a ceiling on central effect; meta-analytic odds ratios for sexual dysfunction in methadone versus buprenorphine maintenance run around 4. The clinical picture is decreased libido, erectile dysfunction, fatigue, and reduced bone density. Testosterone replacement in OPIAD restores libido, erectile function, and quality of life in short-term trials, but does not address the upstream opioid problem. Sources: Brennan 2013 OPIAD review, Yee et al. 2014 IJIR meta-analysis, Bawor et al. 2014, PMC4070102, Daniell 2002 (early OPIAD description), Hallinan et al. 2009 (methadone vs buprenorphine testosterone). Confidence: C1 for the existence and HPG mechanism, C2 for prevalence numbers, C2 for the methadone-vs-buprenorphine gap.

Alcohol's effects on libido split into the well-known acute disinhibitory phase, in which low doses raise self-reported desire while reliably impairing erectile capacity and orgasm latency, and the much more consequential chronic story. Heavy and long-standing intake suppresses Leydig-cell testosterone synthesis directly and accelerates hepatic testosterone catabolism, while elevating SHBG as part of the cirrhotic phenotype, with the net effect of reducing both total and free testosterone. A 2024 meta-analysis by Santi et al. in Andrology pooled cross-sectional and cohort data and found significant reductions in total testosterone, free testosterone, and SHBG with chronic heavy alcohol consumption, alongside decreased LH-to-testosterone ratios suggesting both central and gonadal damage. In advanced alcoholic cirrhosis the picture becomes severe: roughly 90% of men have low testosterone and 72% report decreased libido and sexual potency, with the contributing mechanisms now including testicular atrophy, hyperestrogenism from impaired hepatic clearance, hypothyroidism, and malnutrition. The clinical bottom line is that occasional drinking is a sexual nuisance; alcohol-use disorder is a libido demolisher. Sources: Emanuele & Emanuele 1998 ARCM review, PMC6761906, Santi et al. 2024 Andrology meta-analysis, Maneesh et al. 2006 J Endocrinol Invest. Confidence: C2.

Cannabis is mixed in a way that often gets misreported. Acute use frequently increases self-reported sexual interest and frequency in survey data — the Sun and Eisenberg 2017 NHANES analysis showed cannabis users reported higher coital frequency than non-users — but heavy chronic use and cannabis use disorder show negative associations with testosterone, erectile function, and sperm parameters. Animal studies of THC consistently show suppressed copulatory behaviour and reduced LH pulsatility, mediated through hypothalamic CB1 receptors on kisspeptin-GnRH neurons. Human evidence is messier: total testosterone is usually unchanged or slightly elevated in current users (potentially because smoking close to a sample raises acute testosterone), but cannabis-dependent men show higher rates of erectile dysfunction and clinically defined hypogonadism in larger contemporary databases. The honest reading is that occasional cannabis use is unlikely to dampen libido in most users and may augment desire through anxiolysis and disinhibition; daily heavy use, particularly with cannabis use disorder, plausibly suppresses the HPG axis and impairs erectile function. Sources: Sun & Eisenberg 2017 J Sex Med, PMID 28395129, Payne et al. 2019 Sex Med Rev (cannabis & male fertility), Barbonetti et al. 2024 Andrology, Pizzol et al. 2019 (cannabis & sexual dysfunction). Confidence: C2-C3.

Beta blockers are an instructive case where drug class talk obscures real differences. Older lipophilic beta blockers — propranolol especially, with its high CNS penetration, and to a lesser degree atenolol and metoprolol — show consistent associations with decreased libido and erectile dysfunction in observational and randomised data. The mechanisms include CNS sympathetic blunting that reduces arousal, peripheral β-adrenergic effects on penile vascular smooth muscle, and possible mild reductions in serum testosterone. A meta-analysis of randomised trials by Ko et al. 2002 estimated an absolute increase of about 5 cases of ED per 1,000 patient-years on beta blockers versus placebo, modest but real. Nebivolol, a third-generation beta-1-selective agent that releases nitric oxide via β3-receptor activation, breaks the pattern: in head-to-head trials against atenolol, metoprolol, and bisoprolol it has consistently preserved or improved erectile function (roughly 69% improvement at 3 months in Brixius et al.'s switch study), making it the preferred beta blocker when sexual function is a clinical priority. Sources: Ko et al. 2002 JAMA, PMID 12132976, Brixius et al. 2007, PMID 17593175, Cordero et al. 2010 J Hypertens. Confidence: C2.

Statins and erectile dysfunction is one of the most-debated minor associations in cardiovascular medicine and a useful illustration of how mechanism-spinning can run in both directions. The competing stories are: statins lower cholesterol and improve endothelial nitric-oxide signalling, which should improve erectile function; and statins reduce HMG-CoA reductase activity and steroidogenic substrate, with case reports of decreased libido and modestly lower testosterone. Both have empirical support. Kostis & Dobrzynski's 2014 meta-analysis of randomised trials reported an IIEF-5 improvement of about 3.4 points with statins versus control, suggesting net benefit, while a separate meta-analysis by Cui et al. 2014 found no significant association with new-onset ED. More recent Mendelian-randomisation and pharmacovigilance work has been mixed, with some signals for atorvastatin specifically. The honest summary is that the average patient probably gains slightly more from statin-driven endothelial repair than they lose to any direct steroidogenic effect, but a minority of patients report a clear libido drop on initiation that resolves on discontinuation, and that minority is real. Sources: Kostis & Dobrzynski 2014 J Sex Med, PMID 24684744, Cui et al. 2014 J Sex Med (no association meta-analysis), Davis et al. 2017 Am J Med. Confidence: C3.

The other classical antihypertensives merit a single condensed paragraph because they were the prototype iatrogenic libido suppressors in 1970s-80s data. Thiazide diuretics reproducibly increase erectile dysfunction in randomised trials (TOMHS in particular), with mechanisms still imperfectly defined but probably involving zinc and magnesium losses, mild reductions in penile vascular smooth muscle responsiveness, and possible modest testosterone effects. Methyldopa and clonidine — central α2 agonists — consistently decrease libido, with clonidine in particular reducing genital sympathetic outflow and producing fatigue and dysphoria that confound the sexual picture. Reserpine, now largely historical, depleted central catecholamines and was strongly associated with depression and decreased libido. ACE inhibitors and angiotensin-receptor blockers, by contrast, are roughly neutral or slightly beneficial on sexual function in randomised data, making them along with nebivolol the preferred antihypertensives in sexually-active patients. Sources: Grimm et al. 1997 (TOMHS), PMID 8980797, Wassertheil-Smoller et al. 1991 Ann Intern Med (diuretics & sexual function), PMID 1746997, Manolis & Doumas 2008 J Hypertens review. Confidence: C2.

H2-receptor antagonists are mostly a historical entry. Cimetidine, the first-generation H2 blocker, is a weak but real androgen-receptor antagonist with affinity at roughly 10⁻⁵ of metribolone — clinically negligible at typical reflux doses but enough at the high doses once used for Zollinger-Ellison or refractory ulcer disease to produce reduced libido, erectile dysfunction, and reversible gynecomastia in a subset of men. Ranitidine, famotidine, and the proton-pump inhibitors do not share this effect and have effectively replaced cimetidine in the indications where the antiandrogen activity mattered. Sources: Peden et al. 1979 Lancet, PMID 88646, Sabesin 1993 review, Wang et al. 2008 (cimetidine antiandrogen review). Confidence: C2.

Chronic glucocorticoid therapy belongs in the same picture as opioids: secondary hypogonadism via central HPG suppression. Prednisone or equivalent at doses as low as 5 mg/day chronically can lower serum testosterone, and at the higher doses used in lupus, GCA, transplant, and IBD patients the effect is reliable, with mean total testosterone roughly 35% lower in current glucocorticoid users than in former users in cohort comparisons. The mechanism is multifactorial: glucocorticoids inhibit hypothalamic GnRH and pituitary LH release, directly suppress Leydig cell steroidogenesis, and increase visceral adiposity, which raises aromatase activity and lowers free androgen further. The clinical result is decreased libido, erectile dysfunction, and accelerated bone loss in patients already at high osteoporosis risk. Anabolic-androgenic steroid use, often missed, produces a related but distinct picture by suppressing endogenous LH and FSH; on cessation, recovery can take 6-18 months and presents during the recovery window as severe hypogonadism with crashed libido — a not-uncommon presentation in performance-enhancing-drug clinics. Sources: MacAdams et al. 1986 Ann Intern Med, PMID 3083749, Whirledge & Cidlowski 2010 (stress, glucocorticoids & reproduction), Rasmussen et al. 2020 review of exogenous glucocorticoids, Rahnema et al. 2014 (AAS-induced hypogonadism), PMID 24636400. Confidence: C2.

Chemotherapy and pelvic radiotherapy deserve only a single paragraph here because the mechanism is direct cytotoxic gonadal injury rather than libido pharmacology. Alkylating agents (cyclophosphamide, busulfan, procarbazine), platinum compounds, and total body irradiation cause Leydig and Sertoli cell loss with corresponding falls in testosterone and inhibin B; pelvic radiation doses above 2-3 Gy to the testes commonly cause permanent azoospermia and partial hypogonadism. The libido consequences are downstream of the resulting hypogonadism, the body-image and depressive impact of cancer treatment itself, and the high prevalence of vascular and neurogenic ED in cancer survivors. Mention this less to enumerate effect sizes than because it is the largest class of patients who arrive in a sexual-medicine clinic with a clearly iatrogenic-but-not-pharmacological libido problem. Sources: Howell & Shalet 2005 review, PMID 16025834, Meistrich 2013 J Androl. Confidence: C2.

Conditions, not drugs, fill out the picture, and several deserve their own attention because they recur as differential diagnoses when a patient presents with low libido on an apparently libido-neutral medication regimen. Hyperprolactinemia from a pituitary prolactinoma produces the same syndrome as drug-induced hyperprolactinemia — low libido, erectile dysfunction in men, oligomenorrhea or amenorrhea in women, sometimes galactorrhea — but with a structural cause that often shows on MRI; serum prolactin above ~200 ng/mL is highly suggestive. Treatment with cabergoline or bromocriptine restores function in about two-thirds of cases and can shrink the tumour. Hypothyroidism produces a more diffuse picture: fatigue and depression dominate, libido is often blunted as part of that, and frank sexual-function questionnaire scores in women with overt hypothyroidism are reduced across all FSFI domains, with lubrication especially affected; the effect is largely reversible with levothyroxine. Hypogonadism — primary (testicular failure from Klinefelter, mumps orchitis, post-trauma, post-chemo) or secondary (Kallmann, post-traumatic brain injury, pituitary disease, opioids, glucocorticoids) — is the textbook organic cause of low libido in men, with a dose-response relationship between morning total testosterone and self-reported sexual desire below roughly 300-350 ng/dL. Sources: Buvat & Lemaire 1997 IJIR, Krysiak et al. 2016 (thyroid & sexual function review), PMID 30057137, Bhasin et al. 2018 Endocrine Society testosterone guideline. Confidence: C2.

Major depressive disorder is itself a major libido suppressor independent of any treatment, and confounds antidepressant attribution badly. About 35-50% of people with untreated major depression report reduced sexual desire prior to any drug exposure, with the magnitude tracking depression severity. The mechanism likely overlaps with anhedonia generally — decreased mesolimbic dopamine reward signalling, blunted incentive salience for previously rewarding stimuli, and HPA axis dysregulation. This is why baseline assessment of libido before starting an antidepressant is methodologically important, and why studies that fail to capture pre-treatment sexual function consistently overestimate drug-attributable sexual side effects. Chronic stress and HPA-axis activation produce a related blunting through cortisol's competition with gonadal steroids for shared substrate and through direct CRH-mediated suppression of GnRH; in a UBC cohort of 275 women, those meeting criteria for hypoactive sexual desire disorder showed flatter cortisol curves and blunted cortisol awakening responses. Sleep deprivation joins the same axis: 5 hours/night for 8 nights drops daytime testosterone by 10-15% in young healthy men, and total sleep deprivation more dramatically still, with corresponding subjective drops in vigour and desire. Cardiovascular disease (vascular ED through endothelial dysfunction) and diabetes mellitus (microvascular disease, autonomic neuropathy, and concurrent hypogonadism) round out the most common organic contributors, especially in older men, where they produce the erectile component first and the libido component as a secondary consequence of repeated sexual failure. Sources: Kennedy et al. 1999 (depression & sexual function), Basson et al. 2019 (HPA axis in HSDD), Leproult & Van Cauter 2011 JAMA (sleep & testosterone), PMID 21632481, Defeudis et al. 2022 Front Endocrinol (diabetes & ED). Confidence: C2.

Finally, the question that motivated this dive — why synthetic progestins suppress libido — has a multi-mechanism answer that resists single-paragraph caricature. The dominant mechanism in cisgender women on combined oral contraceptives and in trans women on cyproterone or progesterone is HPG-axis suppression: progestins decrease GnRH pulse frequency through progesterone-receptor signalling in kisspeptin neurons of the hypothalamic AVPV and ARC, with consequent reductions in pulsatile LH and FSH and downstream ovarian or testicular steroidogenesis. Lower bioavailable testosterone — already small in cis women, and now driven further down — directly reduces sexual desire in a population in which testosterone is more important to libido than the popular discourse generally credits. Layered on top is SHBG elevation: ethinyl estradiol in COCs roughly doubles SHBG, which means free testosterone falls about twice as much as total testosterone falls. Some progestins add direct AR antagonism: cyproterone is a high-potency AR antagonist whose libido suppression is so reliable that it has been used historically in paraphilia treatment and in chemical-castration regimens for sex offenders; drospirenone is a milder AR antagonist (about 30% of cyproterone's potency) with antimineralocorticoid activity, derived structurally from spironolactone. Older 19-nortestosterone-derived progestins (norethindrone, levonorgestrel) have residual androgenic activity that can blunt the SHBG/testosterone effect and produce a less libido-suppressive profile, which is why some women report better sexual function after switching from a drospirenone or cyproterone-containing pill to a levonorgestrel-containing one. Direct CNS effects of progesterone metabolites — allopregnanolone and other GABAergic neurosteroids — may further dampen motivation and desire through tonic GABA-A potentiation, though this mechanism is most established in mood and anxiety contexts. The compact answer to the original question: synthetic progestins suppress libido through HPG suppression and reduced ovarian/testicular androgens (the dominant pathway), through SHBG-mediated reduction of free testosterone in COCs (a real and quantitatively important second pathway), through direct AR antagonism in CPA and drospirenone (a third pathway, dose-dependent), and possibly through neurosteroid-mediated central effects (a fourth pathway, less well characterised in the libido domain specifically). Sources: Skorupskaite et al. 2014 (kisspeptin & GnRH), PMID 24664141, Zimmerman et al. 2014 meta-analysis of COC and testosterone, PMID 24082040, Oelkers et al. 1995 drospirenone, PMID 7625729, Kuhl 2005 progestin pharmacology review, Davis et al. 2013 (testosterone & female sexual function). Confidence: C2.

Key uncertainties and contested claims

Several claims in the literature that are routinely repeated remain genuinely uncertain and deserve a flagged section rather than a confident summary. Persistent post-SSRI sexual dysfunction (PSSD) cleared the regulatory bar in 2019 with the EMA label change and again with Health Canada in 2021, but its incidence and pathobiology remain contested; the often-cited "1 in 216" figure from Healy et al. 2023 is a model-based estimate from spontaneous-report data, not a population-validated rate, and the mechanism (epigenetic 5-HT1A downregulation, neurosteroid changes, peripheral small-fibre neuropathy, or some combination) has no biomarker yet. Sources: Healy et al. 2023, PMC10122283, Bala et al. 2018 review. Confidence: C4 for incidence and mechanism.

Post-finasteride syndrome is similarly real-enough-to-label-warn but underdetermined. Melcangi's group has documented neurosteroid abnormalities and pudendal somatosensory evoked potential changes in PFS patients, but the FDA explicitly stated in its 2022 label update that available data did not establish causation for persistent sexual dysfunction beyond the rare cases already labelled, and added only depression and suicidal ideation as new adverse reactions. The discrepancy between original-trial sexual side-effect rates (low single digits) and the much louder anecdotal cohort is unresolved; pre-existing depression in alopecia patients, body-image confounding, and a real but rare neuroendocrine phenotype probably each contribute. Sources: Melcangi et al. 2017, PMID 28408350, PROPECIA 2022 FDA label, Pereira & Coelho 2020 PMC7253896. Confidence: C4.

The statin-libido relationship remains genuinely net-uncertain. Some randomised data suggest improvement in erectile function via endothelial mechanisms, other meta-analyses find no effect, and pharmacovigilance signals exist for atorvastatin specifically. The honest position is that statins are unlikely to be a major libido dampener for most patients, and may even slightly improve sexual function via endothelial repair, while a real subset experiences a libido drop on initiation that resolves on discontinuation. Sources: Kostis & Dobrzynski 2014, PMID 24684744, Cui et al. 2014, PMID 24628781. Confidence: C3.

The "drug holiday" strategy for SSRI sexual side effects is widely recommended in clinical practice but has only modest controlled support, and it pharmacokinetically cannot work for fluoxetine because of norfluoxetine's long half-life. Sources: Rothschild 1995 case series. Confidence: C3.

Cannabis-libido associations remain among the messiest in the iatrogenic literature. Acute use is reported as desire-augmenting in surveys, while heavy chronic use and cannabis use disorder show negative associations in clinical cohorts; the two findings can be reconciled but are easy to misreport. Animal HPG suppression is consistent; human testosterone changes are inconsistent. Sources: Sun & Eisenberg 2017, PMID 28395129, Pizzol et al. 2019, PMC8631840. Confidence: C3.

The relative contribution of progestin-driven SHBG elevation versus direct CNS neurosteroid effects to libido suppression in COC-related sexual dysfunction is unresolved. Population studies show only weak correlations between measured testosterone changes and self-reported sexual function changes on the pill, suggesting either that individual variation in sensitivity is large, that non-androgen mechanisms (mood, neurosteroid GABAergic effects, partner factors) carry substantial weight, or both. Sources: Pastor et al. 2013 J Sex Med, Zethraeus et al. 2016 JCEM (COC & sexual function RCT). Confidence: C3.

Finally, the treatment of opioid-induced androgen deficiency by testosterone replacement improves short-term libido and sexual function but does not fix the underlying opioid dependence and may obscure the case for opioid taper or rotation to buprenorphine. The right clinical position in 2026 is that OPIAD diagnosis should prompt a discussion of opioid reduction or substitution before reflexive testosterone repletion. Sources: Brennan 2013 review, Yee et al. 2014, IJIR. Confidence: C2.